A new study by Daniel Haller, MD shows new drug combination helps colon cancer patients


January 21, 2010

BusinessWeek

Daniel Haller, MD
, a professor in the division of Hematology/Oncology, is quoted in a BusinessWeek story (via HealthDay) about his new study, presented this week at the ASCO Gastrointestinal Cancers Symposium, showing that adjuvant treatment with XELOX -- a combination of capecitabine and oxaliplatin -- was more effective than standard drug therapy for slowing the progression of stage III colon cancer in patients of all ages. "While treatment decisions shoudl be made on an individual basis, these findings shed important new light on how we can best treat otherwise healthy patients age 70 and older," he says. Read More

More Coverage
NCI Cancer Bulletin
HemOnc today Story
US News & World Report